Receives April 21 "approvable" letter. The nonbenzodiazepine hypnotic zolpidem tartrate, which was developed by the Searle/Synthelabo joint venture Lorex, has been pending approval at FDA since January 1989. FDA's Drug Abuse Advisory Committee recently voted by a narrow margin to classify zolpidem as a Schedule V drug ("The Pink Sheet" March 2, T&G-5). Benzodiazepine hypnotics are Schedule IV, a slightly more restrictive category. Ambien will be zolpidem's trade name in North America, where Searle has marketing rights. In Europe, where Synthlabo markets the drug, the brandname is Stilnox.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth